Cyclic AMP increases COX-2 expression via mitogen-activated kinase in human myometrial cells

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 7, 2012, Pages 1447-1460

  Chen, Li ^a,b   Sooranna, Suren R ^a   Lei, Kaiyu ^a   Kandola, Mandeep ^a   Bennett, Phillip R ^a   Liang, Zhiqing ^b   Grammatopoulos, Dimitri ^c   Johnson, Mark R ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Cyclic AMP; Cycloxygenase 2; Human myometrium; Prostaglandins

Indexed keywords

8 BROMO CYCLIC AMP; CYCLIC AMP; CYCLOOXYGENASE 2; FORSKOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN E2; PTGS2 PROTEIN, HUMAN; ROLIPRAM; SMALL INTERFERING RNA;

ARTICLE; CELL CULTURE; CYTOLOGY; DNA SEQUENCE; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MYOMETRIUM; PHOSPHORYLATION;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; CELLS, CULTURED; CYCLIC AMP; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; FORSKOLIN; GENE EXPRESSION REGULATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MYOMETRIUM; PHOSPHORYLATION; RNA, SMALL INTERFERING; ROLIPRAM; SEQUENCE ANALYSIS, DNA;

EID: 84863095392     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01413.x     Document Type: Article

References (37)

1. MacDorman MF, Mathews TJ. Behind international rankings of infant mortality: how the United States compares with Europe. NCHS Data Brief; 2009. p. 1-8.
2. Meloni A, Melis M, Alba E, et al. Medical therapy in the management of preterm birth. J Matern Foetal Neonatal Med. 2009; Suppl 3: 72-6.
3. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2005. Natl Vital Stat Rep. 2007; 56: 1-103.
4. Goldenberg RL, Culhane JF, Iams JD, et al. Epidemiology and causes of preterm birth. Lancet. 2008; 371: 75-84.
5. Landau R, Morales MA, Antonarakis SE, et al. Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor. Clin Pharmacol Ther. 2005; 78: 656-63.
6. Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med. 2007; 357: 477-87.
7. Mehats C, Schmitz T, Oger S, et al. PDE4 as a target in preterm labour. BMC Pregnancy Childbirth. 2007; Suppl 1: S12.
8. Sparey C, Robson SC, Bailey J, et al. The differential expression of myometrial connexin-43, cyclooxygenase-1 and -2, and Gs alpha proteins in the upper and lower segments of the human uterus during pregnancy and labor. J Clin Endocrinol Metab. 1999; 84: 1705-10.
9. Olson DM, Ammann C. Role of the prostaglandins in labour and prostaglandin receptor inhibitors in the prevention of preterm labour. Front Biosci. 2007; 12: 1329-43.
10. Blumenfeld YJ, Lyell DJ. Prematurity prevention: the role of acute tocolysis. Curr Opin Obstet Gynecol. 2009; 21: 136-41.
11. Kaminski K, Rechberger T, Oleszczuk J, et al. Biochemical and clinical evaluation of the efficiency of intracervical extraamniotic prostaglandin F2 alpha and intravenous oxytocin infusion to induce labour at term. Aust N Z J Obstet Gynaecol. 1994; 34: 409-13.
12. Cao Z, Liu LZ, Dixon DA, et al. Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell Signal. 2007; 19: 1542-53.
13. Oyesanya RA, Lee ZP, Wu J, et al. Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. Faseb J. 2008; 22: 2639-51.
14. Slater DM, Berger LC, Newton R, et al. Expression of cyclooxygenase types 1 and 2 in human foetal membranes at term. Am J Obstet Gynecol. 1995; 172: 77-82.
15. Zakar T, Olson DM, Teixeira FJ, et al. Regulation of prostaglandin endoperoxide H2 synthase in term human gestational tissues. Acta Physiol Hung. 1996; 84: 109-18.
16. Mohan AR, Sooranna SR, Lindstrom TM, et al. The effect of mechanical stretch on cyclooxygenase type 2 expression and activator protein-1 and nuclear factor-kappaB activity in human amnion cells. Endocrinology. 2007; 148: 1850-7.
17. Jung WK, Lee DY, Park C, et al. Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases. Br J Pharmacol. 2010; 159: 1274-85.
18. Minguet S, Huber M, Rosenkranz L, et al. Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur J Immunol. 2005; 35: 31-41.
19. Fetalvero KM, Zhang P, Shyu M, et al. Prostacyclin primes pregnant human myometrium for an enhanced contractile response in parturition. J Clin Invest. 2008; 118: 3966-79.
20. Sun H, Xu B, Inoue H, et al. P38 MAPK mediates COX-2 gene expression by corticosterone in cardiomyocytes. Cell Signal. 2008; 20: 1952-9.
21. Yaqub S, Tasken K. Role for the cAMP-protein kinase A signaling pathway in suppression of antitumour immune responses by regulatory T cells. Crit Rev Oncog. 2008; 14: 57-77.
22. Wadhwa S, Choudhary S, Voznesensky M, et al. Fluid flow induces COX-2 expression in MC3T3-E1 osteoblasts via a PKA signaling pathway. Biochem Biophys Res Commun. 2002; 297: 46-51.
23. Faour WH, Gomi K, Kennedy CR. PGE(2) induces COX-2 expression in podocytes via the EP(4) receptor through a PKA-independent mechanism. Cell Signal. 2008; 20: 2156-64.
24. Xu XJ, Reichner JS, Mastrofrancesco B, et al. Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production. J Immunol. 2008; 180: 2125-31.
25. Sooranna SR, Engineer N, Loudon JA, et al. The MAPK dependent expression of prostaglandin H synthase-2 and interleukin 8 mRNA by myometrial cells: the differential effect of stretch and interleukin-1{beta}. J Clin Endocrinol Metab. 2005; 90: 3517-27.
26. Yin F, Wang YY, Du JH, et al. Noncanonical cAMP pathway and p38 MAPK mediate beta2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts. J Mol Cell Cardiol. 2006; 40: 384-93.
27. + channels in cerebellar neurons. Proc Natl Acad Sci U S A. 2007; 104: 2519-24.
28. Amsen EM, Pham N, Pak Y, et al. The guanine nucleotide exchange factor CNrasGEF regulates melanogenesis and cell survival in melanoma cells. J Biol Chem. 2006; 281: 121-8.
29. Schroer K, Zhu Y, Saunders MA, et al. Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation. 2002; 105: 2760-5.
30. Subbaramaiah K, Chung WJ, Dannenberg AJ. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem. 1998; 273: 32943-9.
31. Kirtikara K, Raghow R, Laulederkind SJ, et al. Transcriptional regulation of cyclooxygenase-2 in the human microvascular endothelial cell line, HMEC-1: control by the combinatorial actions of AP2, NF-IL-6 and CRE elements. Mol Cell Biochem. 2000; 203: 41-51.
32. Wu MH, Wang CA, Lin CC, et al. Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. J Clin Endocrinol Metab. 2005; 90: 286-95.
33. Matsuura H, Sakaue M, Subbaramaiah K, et al. Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases. J Biol Chem. 1999; 274: 29138-48.
34. Streicher JM, Ren S, Herschman H, et al. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res. 2010; 106: 1434-43.
35. Klein T, Shephard P, Kleinert H. Regulation of cyclooxygenase-2 expression by cyclic AMP. Biochim Biophys Acta. 2007; 1773: 1605-18.
36. Simpkin JC, Kermani F, Palmer AM, et al. Effects of corticotrophin releasing hormone on contractile activity of myometrium from pregnant women. Br J Obstet Gynaecol. 1999; 106: 439-45.
37. Schmitz T, Souil E, Herve R, et al. PDE4 inhibition prevents preterm delivery induced by an intrauterine inflammation. J Immunol. 2007; 178: 1115-21.